Solid Tumors, No Specified Mutations

- **10145**: Phase Ib Combination Study of Copanlisib and Nivolumab in Advanced Solid Tumors and Lymphomas
- **10014**: A Pilot Study of Atezolizumab (MPDL3280A) Following Adoptive Cell Transfer in Active Hematologic or Solid Tumor Malignancies
- **9914**: A Phase I Study of a Combination of MM-398 and Veliparib in Solid Tumors
- **9938**: Phase I Clinical Trial of VX-970 in Combination with the Topoisomerase I Inhibitor Irinotecan in Patients with Advanced Solid Tumors
- **10204**: Phase Ib Study of Nivolumab in Patients with Autoimmune Disorders and Advanced Malignancies (AIM-NIVO)
- **10061**: A Phase 1 Study of MK-3475 (Pembrolizumab) in Combination with Recombinant Interleukin-12 in Patients with Solid Tumors
- **10294**: DURVA+: Evaluation of the Safety and Pharmacodynamics of Anti-PD-L1 Antibody MEDI4736 (Durvalumab) in Combination with Chemotherapy in Patients with Advanced Solid Tumors
- **10299**: A Phase I Study to Investigate the Safety of the Ubiquitin Activating Enzyme Inhibitor TAK-243 in Adult Solid Tumor and Lymphoma Patients
- **10315**: A Phase II Study of XL184 (Cabozantinib) in Combination with Nivolumab and Ipilimumab for the Treatment of Poorly Differentiated Neuroendocrine Carcinomas
- **10363**: A Phase I Study of Pomalidomide and Nivolumab in Patients with Virus-Associated Malignancies in Patients with or Without HIV
- **10349**: A Phase I Trial of the P97 Inhibitor CB-5339 in Patients with Advanced Solid Tumors and Lymphomas

**NOTE**: * No ClinicalTrials.gov webpage is available at this time (typically for approved LOIs or protocols in review); ▼ Limited trial; not open ETCTN-wide; Version Date: April 17, 2020